Exact Mass: 528.103109
Exact Mass Matches: 528.103109
Found 180 metabolites which its exact mass value is equals to given mass value 528.103109,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
dTDP-3,4-dioxo-2,6-dideoxy-D-glucose
Mahuannin D
A proanthocyanidin isolated form Ephedra sinica.
dTDP-2,6-dideoxy-D-glycero-hex-2-enos-4-ulose
dTDP 1-ester with (6S)-5,6-dihydro-4-hydroxy-6-methyl-5-oxo-2H-pyran
(5-{5,7-dihydroxy-4-oxo-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-4H-chromen-2-yl}-2-hydroxyphenyl)oxidanesulfonic acid
Cefquinome
Lactose citrate
1H-Cyclohepta(ghi)perylene-5,12-dione, 3-acetyl-6,11-dihydroxy-4,8,9,13-tetramethoxy-2-methyl-
D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents D003879 - Dermatologic Agents
Hypocrellin C
Hypocrellin b is a natural product found in Shiraia bambusicola with data available. Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities[1][2][3]. Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities[1][2][3].
HypocrellinC
Hypocrellin b is a natural product found in Shiraia bambusicola with data available. Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities[1][2][3]. Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities[1][2][3].
2-(4-Hydroxyphenyl)-3-(2,4-dihydroxybenzoyl)-5,4-[4,6-dihydroxy-1,2-phenyleneoxy(4-hydroxyphenylmethylene)]tetrahydrofuran
Daphnodorin J
Thalassiolin A
Quercetin 3-rhamnoside-3-sulfate
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2,4,6-trihydroxy-3-(4-hydroxybenzoyl)phenyl]oxan-3-yl] 4-hydroxybenzoate
O-(4-deoxy-alpha-L-erythro-hex-4-enopyranosyluronic acid)-(1<*>4)-O-(beta-D-mannopyranuronic acid)-(1<*>4)-O-D-mannopyranuronic acid
Chrysoaphin-sl-1|Chrysoaphin-sl-2|chrysoaphin-Slambda-2
3,5-dihydroxy-2-[(4-hydroxyphenyl)carbonyl]phenyl 6-O-[(4-hydroxyphenyl)carbonyl]-beta-D-glucopyranoside|iriflophenone 2-O-[6-O-(4-hydroxybenzoyl)]-beta-D-glucopyranoside
2-methoxy-5-(1,2,3-trihydroxypropyl)-phenyl-1-O-(6-galloyl)-beta-D-glucopyranoside|2-Methoxy-5-(1,2,3-trihydroxypropyl)-phenyl-1-O-(6-galloyl)-??-D-glucopyranoside
3-ethenyl-4-[2-(3,4,5-trihydroxybenzoyl)oxyethyl]-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
hovenin A|{(2R,3R)-3,5,7,5-tetrahydroxy-2-[(2R,3R)-3-(4-hydroxy-3,5-dimethoxyphenyl)-2-hydroxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-yl]-chroman-4-one}
D-threo-guaiacylglycerol 8-O-beta-D-(6-O-galloyl)glucopyranoside
1-(3-beta-D-glucosyloxy-4-hydroxyphenyl)-3-hydroxymethyl-4-methoxy-6,7-methylenedioxy-2-naphthoic acid lactone|justalakonin
2-(4-Hydroxyphenyl)-3-(2,4-dihydroxybenzoyl)-4-(4-hydroxybenzoyl)-5-(2,4-dihydroxyphenyl)tetrahydrofuran
Oenin
C23H25ClO12 (528.1034480000001)
Primulin_(anthocyanin)
C23H25ClO12 (528.1034480000001)
Malvidin 3-galactoside is an anthocyanidin glycoside.
(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2,4,6-trihydroxy-3-(4-hydroxybenzoyl)phenyl]oxan-3-yl] 4-hydroxybenzoate
(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid [IIN-based: Match]
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2,4,6-trihydroxy-3-(4-hydroxybenzoyl)phenyl]oxan-3-yl] 4-hydroxybenzoate [IIN-based: Match]
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2,4,6-trihydroxy-3-(4-hydroxybenzoyl)phenyl]oxan-3-yl] 4-hydroxybenzoate [IIN-based on: CCMSLIB00000847571]
N2-Aristololactam-II-deoxyguanosine
C26H20N6O7 (528.1393410000001)
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2,4,6-trihydroxy-3-(4-hydroxybenzoyl)phenyl]oxan-3-yl] 4-hydroxybenzoate_major
Cys Asp Glu Tyr
C21H28N4O10S (528.1526068000001)
Cys Asp Tyr Glu
C21H28N4O10S (528.1526068000001)
Cys Glu Asp Tyr
C21H28N4O10S (528.1526068000001)
Cys Glu Tyr Asp
C21H28N4O10S (528.1526068000001)
Cys Tyr Asp Glu
C21H28N4O10S (528.1526068000001)
Cys Tyr Glu Asp
C21H28N4O10S (528.1526068000001)
Asp Cys Glu Tyr
C21H28N4O10S (528.1526068000001)
Asp Cys Tyr Glu
C21H28N4O10S (528.1526068000001)
Asp Glu Cys Tyr
C21H28N4O10S (528.1526068000001)
Asp Glu Tyr Cys
C21H28N4O10S (528.1526068000001)
Asp Tyr Cys Glu
C21H28N4O10S (528.1526068000001)
Asp Tyr Glu Cys
C21H28N4O10S (528.1526068000001)
Glu Cys Asp Tyr
C21H28N4O10S (528.1526068000001)
Glu Cys Tyr Asp
C21H28N4O10S (528.1526068000001)
Glu Asp Cys Tyr
C21H28N4O10S (528.1526068000001)
Glu Asp Tyr Cys
C21H28N4O10S (528.1526068000001)
Glu Tyr Cys Asp
C21H28N4O10S (528.1526068000001)
Glu Tyr Asp Cys
C21H28N4O10S (528.1526068000001)
Tyr Cys Asp Glu
C21H28N4O10S (528.1526068000001)
Tyr Cys Glu Asp
C21H28N4O10S (528.1526068000001)
Tyr Asp Cys Glu
C21H28N4O10S (528.1526068000001)
Tyr Asp Glu Cys
C21H28N4O10S (528.1526068000001)
Tyr Glu Cys Asp
C21H28N4O10S (528.1526068000001)
Tyr Glu Asp Cys
C21H28N4O10S (528.1526068000001)
nickel(2+),1-[[6-[(2-oxidonaphthalen-1-yl)methylideneamino]-2-oxo-1,3-dihydrobenzimidazol-5-yl]iminomethyl]naphthalen-2-olate
C29H18N4NiO3 (528.0732307999999)
[1,1-Binaphthalene]-2,2-diol, 3,3-bis(4-nitrophenyl)-, (1S)
Sivelestat Sodium
C20H29N2NaO11S (528.1389684000001)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Nizofenone fumarate
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D020011 - Protective Agents
3-ethenyl-4-[2-(3,4,5-trihydroxybenzoyl)oxyethyl]-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranose
C17H28N3O12P2- (528.1148168000001)
dTDP-3-amino-4-dehydro-2,3,6-trideoxy-alpha-D-glucose
dTDP-3-amino-4-dehydro-2,3,6-trideoxy-beta-L-glucose
(2S,3R,4S)-2-[(2S,3R,4R,5R,6S)-2-carboxy-6-[(2S,3R,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
4-O-[4-O-(4-Deoxy-beta-L-threo-hexa-4-enopyranuronosyl)-alpha-D-galactopyranuronosyl]-alpha-D-galactopyranuronic acid
7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1,8,9,10-Tetrahydroxy-5-(hydroxymethyl)-7-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,6,11,15-tetraoxatricyclo[7.3.3.05,10]pentadecane-3,12,14-trione
ent-apigeniflavan-(2alpha->7,4alpha->8)-epiafzelechin
3-[[2-(4-Bromophenyl)-1-oxoethyl]amino]-3-[4-[(4-fluorophenyl)methylamino]-3-nitrophenyl]propanamide
N-[[(4S,5S)-8-bromo-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide
N-[[(4R,5S)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide
6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonic acid
3,4,5-trihydroxy-6-[[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-5-sulino-3,4-dihydro-2H-chromen-7-yl]oxy]oxane-2-carboxylic acid
(3R,4S)-2-[(2S,3R,4R,5R)-2-carboxy-6-[(2S,4R,5R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
(2S,3R,4R)-3,4-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-3,4-dihydro-2H-pyran-2,6-dicarboxylic acid
3-[2-O-(4-Hydroxybenzoyl)-beta-D-glucopyranosyl]-2,4,4,6-tetrahydroxybenzophenone
dTDP-3,4-didehydro-2,6-dideoxy-alpha-D-glucose
A dTDP-sugar having 3,4-didehydro-2,6-dideoxy-alpha-D-glucose as the sugar component.
[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] [(2R,6R)-4-hydroxy-6-methyl-5-oxo-2H-pyran-2-yl] hydrogen phosphate
dTDP-4-dehydro-2,6-dideoxy-alpha-D-glucose(2-)
A nucleotide-sugar oxoanion obtained by deprotonation of the diphosphate OH groups of dTDP-4-dehydro-2,6-dideoxy-alpha-D-glucose; major species at pH 7.3.
dTDP-4-(methylammonio)-2,3,4,6-tetradeoxy-alpha-D-glucose(1-)
C17H28N3O12P2 (528.1148168000001)
A nucleotide-sugar oxoanion arising from deprotonation of the diphosphate OH groups and protonation of the amino group of dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-glucose; major species at pH 7.3.
(5-{5,7-dihydroxy-4-oxo-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-4H-chromen-2-yl}-2-hydroxyphenyl)oxidanesulfonic acid
dTDP 1-ester with (6R)-5,6-dihydro-4-hydroxy-6-methyl-5-oxo-2H-pyran
3-Carboxy-1-hydroxypropylthiamine diphosphate
A 1,3-thiazolium cation that is 1,3-thiazol-3-ium substituted by a methyl group at position 4, a (4-amino-2-methylpyrimidin-5-yl)methyl group at position 3, a 3-carboxy-1-hydroxypropyl at position 2 and a 2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl group at position 5.
KRAS G12C inhibitor 19
C25H19ClF2N4O3S (528.0834398000001)
KRAS G12C inhibitor 19 is a potent inhibitor of KRAS G12C. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1)[1].
PSB-603
PSB-603 is a potent and highly selective A2B adenosine receptor antagonist exhibiting a Ki value of 0.553 nM and virtually no affinity for the human and rat A1 and A2A and the human A3 receptors up to a concentration of 10 μM[1].
UGT8-IN-1
UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders[1].
[(2r,3s,4s,5r,6r)-6-{[(1r,2s)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate
3,4-bis({[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy})-3,4-dihydro-2h-pyran-2,6-dicarboxylic acid
[(2r,3s,4s,5r,6r)-6-{[(1s,2s)-1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate
4,5,6-trihydroxy-2,3-dimethyl-9-{4,5,6-trihydroxy-2-methyl-8-oxocyclohexa[g]chromen-9-yl}cyclohexa[g]chromen-8-one
5-[(10s,11s)-10-(3,5-dihydroxyphenyl)-11-(4-hydroxy-3-methoxyphenyl)-2-methoxy-4,12-dioxatricyclo[7.3.0.0³,⁷]dodeca-1(9),2,5,7-tetraen-5-yl]benzene-1,3-diol
8-O-galloyl desbenzoylpaeoniflorin
{"Ingredient_id": "HBIN013857","Ingredient_name": "8-O-galloyl desbenzoylpaeoniflorin","Alias": "NA","Ingredient_formula": "C23H28O14","Ingredient_Smile": "CC12CC3(C4CC1(C4(C(O2)O3)COC(=O)C5=CC(=C(C(=C5)O)O)O)OC6C(C(C(C(O6)CO)O)O)O)O","Ingredient_weight": "528.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "34553","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "15450040","DrugBank_id": "NA"}